Assignee
BETA PHARMA INC
US·15 granted patents·6 pending applications·27 citations·filing 2003–2023
Top patents by PatentIndex Score
21 records- 0187US9878994B22-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2015·Granted Jan 30, 2018·8 cites·32 claims
- 0285US10239864B22-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2018·Granted Mar 26, 2019·5 cites·20 claims
- 0376US10590111B2Substituted 2-anilinopyrimidine derivatives as EGFR modulatorsBETA PHARMA INC·Filed 2015·Granted Mar 17, 2020·2 cites·39 claims
- 0476US7078409B2Fused quinazoline derivatives useful as tyrosine kinase inhibitorsBETA PHARMA INC·Filed 2003·Granted Jul 18, 2006·12 cites·16 claims
- 0569US12187707B2Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereofBETA PHARMA INC·Filed 2021·Granted Jan 7, 2025·0 cites·13 claims
- 0665US11180478B2Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereofBETA PHARMA INC·Filed 2018·Granted Nov 23, 2021·0 cites·15 claims
- 0761US11414401B2Substituted 2-anilinopyrimidine derivatives as EGFR modulatorsBETA PHARMA INC·Filed 2020·Granted Aug 16, 2022·0 cites·7 claims
- 0860US2025276968A18- and 6-substituted pyridopyrimidine derivatives as kras inhibitorsBETA PHARMA INC·Filed 2023·Application pending·0 cites
- 0959US10844045B2Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereofBETA PHARMA INC·Filed 2017·Granted Nov 24, 2020·0 cites·23 claims
- 1058US2025250286A1Fused pyrimidine derivatives as kras oncoprotein inhibitorsBETA PHARMA INC·Filed 2022·Application pending·0 cites
- 1156US11052086B22-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancersBETA PHARMA INC·Filed 2017·Granted Jul 6, 2021·0 cites·7 claims
- 1256US9359370B2Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereofBETA PHARMA INC·Filed 2014·Granted Jun 7, 2016·0 cites·13 claims
- 1354US11352341B22H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2019·Granted Jun 7, 2022·0 cites·19 claims
- 1454US2024140948A1Pyridopyrimidine derivatives as kras inhibitorsBETA PHARMA INC·Filed 2022·Application pending·0 cites
- 1553US12258365B2Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2019·Granted Mar 25, 2025·0 cites·30 claims
- 1652US2023099858A1Pyridopyrimidine derivatives as kras inhibitorsBETA PHARMA INC·Filed 2021·Application pending·0 cites
- 1751US2024002365A1Pyridazine and 1,2,4-triazine derivatives as fgfr kinase inhibitorsBETA PHARMA INC·Filed 2021·Application pending·0 cites
- 1850US12390464B2Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitorsBETA PHARMA INC·Filed 2020·Granted Aug 19, 2025·0 cites·20 claims
- 1946US2022079944A12h-indazole derivatives as therapeutic agents for brain cancers and brain metastasesBETA PHARMA INC·Filed 2020·Application pending·0 cites
- 2044US12595246B2Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereofBETA PHARMA INC·Filed 2020·Granted Apr 7, 2026·0 cites·7 claims
- 2140US9820721B2Aspiration and biopsy needle apparatus and devices and applications thereofBETA PHARMA INC·Filed 2015·Granted Nov 21, 2017·0 cites·38 claims
Join the waitlist — get patent alerts
Get an alert when BETA PHARMA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →